Dr. Peter O'Donnell presented patient-reported outcomes (PROs) from the phase III KEYNOTE-905/EV-303 trial evaluating perioperative enfortumab vedotin (EV) plus pembrolizumab in cisplatin-ineligible ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers oral abstract session. Dr. Thomas Powles presented 3.5-year follow-up data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results